In this summary report, we will take a quick look at the top 5 gainers and losers up or down double digits on the Canadian stock markets. Here is…
depression
Some positive action on psychedelic stocks in the last few days. As a technical analyst, there are good signs indicating a reversal is occurring. The downtrend is over, and…
A Genetic Link I recently started watching Netflix’s Archive 81 with my girlfriend. Although we have only watched the first episode, there is a clear focus on mental health. It…
Filament Health (FH.NE) has released two new press releases since the last time I covered the company back in mid January 2022. Filament Health Corp. operates as a natural psychedelic…
Filament Health (FH.NE) announced today that it has received approval from Health Canada for a Phase 2 clinical trial using PEX010, the Company’s botanical psilocybin drug candidate. Cybin Therapeutics…
$41.189M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has received approval from Health Canada for a Phase 2 clinical trial utilizing the Company’s standardized natural psilocybin…
You’d be hard pressed to find someone who hasn’t been touched by depression or anxiety. Biochemically, they’re considered co-morbid, which means they often happen at the same time and…
Mind Cure Health (MCUR.C) announced the development of two proprietary ketamine-enhanced protocols specifically for pain management and another for depression, according to a press release. Depression is basically…
Delic Holdings (DELC.C) announced that their acquisition target, Ketamine Infusion Centers (KIC), proposed an acquisition of two additional licensed ketamine clinics in Arizona. Back in February, Delic signed a…
Numinus Wellness (NUMI.V) partnered with KGK Science, a contract research organization focusing on natural products, for a few psilocybin extraction clinical trial today, according to a press release. The…